Skip to content
DataLookout
Menu

NCT05063916

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 8 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: \<75% participation Show 5 more changesShow less
    • Eligibility criteria expanded, about 50 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Final enrollment: 9 participants (planned 18)
    • Primary completion date changed from estimate of Aug 1, 2027 to Nov 11, 2026
    • Study description expanded, about 4 words
  2. Notable Primary and study completion dates: Aug 1, 2025 to Aug 1, 2027v15
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v11
  4. Notable Primary and study completion dates: Sep 1, 2023 to Aug 1, 2025v8
  5. Notable Primary and study completion dates: Aug 1, 2025 to Sep 1, 2023v7
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Primary and study completion dates: Aug 1, 2023 to Aug 1, 2025v6
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria shortened, about 1 word
    • Start date changed from estimate of Mar 31, 2022 to Feb 28, 2022
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To establish the progression free survival rate at 6 months (PFS6) in response to AK104 monotherapy in patients with progressive/relapsed high-grade neuroendocrine carcinomas of the cervix
Timeframe: (up to 6 months) through study completion, an average of 1 year

Arms and interventions

AK104Experimental

cadonilimab) can help to control neuroendocrine cervical cancer that is recurrent (has come back after treatment) or metastatic (has spread).

Drugs: AK104

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States